loading

Bristol Myers Squibb Co (BMY) 最新ニュース

pulisher
Jun 18, 2025

Bristol Myers Squibb (BMY) Collaborates on Alzheimer's Drug Deve - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol-Myers (NYSE:BMY) Squibb Dividend Update Reflects Steady Healthcare NYSE Composite - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends - Yahoo

Jun 18, 2025
pulisher
Jun 18, 2025

BioNTech and Bristol Myers Squibb Collaborate on BNT327, a PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol Myers Squibb to present positive new data on lymphoma treatment - Pharmafile

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BM - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BMY Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol Myers Squibb declares quarterly dividend of $0.62 per share By Investing.com - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol Myers Squibb Announces Dividend - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol-Myers Expands in Cancer Care With $1.35B OncoACP3 Deal - Insider Monkey

Jun 17, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 17, 2025

BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Therapy - geneonline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Bristol Myers Squibb (BMY) Shares Cross 5% Yield Mark - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

Myocardial Infarction Market Is Booming So Rapidly 2025-2032 - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Vanguard Health Care Fund's Strategic Moves: A Closer Look at Bristol-Myers Squibb Co - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol Myers Squibb (BMY) Achieves Strong Results with Breyanzi in Lymphoma Study - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol Myers: positive phase 2 data in lymphoma - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol Myers (BMY) Reports Promising Results from Lymphoma Stud - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Schizophrenia Drugs Market Size, Share & Forecast 2025 | Major - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol-Myers Squibb (BMY) Stock Analysis: Healthcare Giant with a 14.77% Potential Upside - DirectorsTalk Interviews

Jun 16, 2025
pulisher
Jun 16, 2025

Business development leadership team - Bristol Myers Squibb

Jun 16, 2025
pulisher
Jun 16, 2025

BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Treatment - geneonline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Rockland Trust Co. Sells 20,035 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Jim Cramer on Bristol Myers: “We Need to See That Stock Back Up at $60” - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

BioNTech and Bristol Myers Squibb Partner to Develop Bispecific Antibody Targeting PD-L1 and VEGF-A for Tumor Treatment - geneonline.com

Jun 14, 2025
pulisher
Jun 14, 2025

Bristol-Myers Squibb’s SWOT analysis: stock outlook amid Cobenfy growth and pipeline potential - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button' - Endpoints News

Jun 13, 2025
pulisher
Jun 12, 2025

Bristol Myers (BMY) Showcases Promising New Data on Targeted Pro - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol-Myers Promotes Attorney To Lead Corporate Affairs - Law360

Jun 12, 2025
pulisher
Jun 12, 2025

BioNTech and Bristol Myers Squibb Partner to Develop BNT327 Antibody Targeting PD-L1 and VEGF-A Pathways in Tumors - geneonline.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu Compared with Placebo in Adults with Psoriatic Arthritis - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol-Myers stock holds steady as Cantor maintains neutral rating By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

BMY Reports Positive Data on Sotyktu From Arthritis Study - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb promotes Wendy Bartie to lead corporate affairs - PR Week UK

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers: new data to be presented in hematology - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol-Myers stock holds steady as Cantor maintains neutral rating - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb presents protein degradation data at EHA By Investing.com - Investing.com India

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb presents protein degradation data at EHA - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb Sets Q2 2025 Earnings Date: Key Financial Results Coming July 31 - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 - The Joplin Globe

Jun 12, 2025
pulisher
Jun 11, 2025

Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - MSN

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers at Goldman Sachs Conference: Strategic Insights on Growth - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal - BioPharma Dive

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers (BMY) Sees Promising Results for Sotyktu in Phase 3 Trial - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol-Myers Squibb To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers: positive data in psoriatic arthritis - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis - BioSpace

Jun 11, 2025
pulisher
Jun 11, 2025

FY2026 Earnings Forecast for BMY Issued By Cantor Fitzgerald - Defense World

Jun 11, 2025
drug_manufacturers_general SNY
$47.86
price up icon 0.50%
$108.50
price up icon 0.46%
drug_manufacturers_general PFE
$23.97
price up icon 0.38%
$289.33
price down icon 0.10%
drug_manufacturers_general MRK
$79.06
price down icon 0.29%
drug_manufacturers_general NVS
$115.77
price down icon 0.16%
大文字化:     |  ボリューム (24 時間):